Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 24 Nov 2022

Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

in Cancer Molecular Targets and Therapeutics

Ankang Hu
Yonghui Wang
Jiahao Tian
Zihan Chen
Renjin Chen
Xufeng Han
Yang Chen
Tingjun Liu
Quangang Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.947054

6,365 views
14 citations

Review

Published on 24 Nov 2022

Circ_0007534 as new emerging target in cancer: Biological functions and molecular interactions

in Cancer Molecular Targets and Therapeutics

Bowen Liu
Chengbin Dong
Quan Chen
Zhenhua Fan
Yu Zhang
Yifan Wu
Ting Cui
Fuquan Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.1031802

2,291 views
1 citation

Case Report

Published on 24 Nov 2022

NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report

in Cancer Molecular Targets and Therapeutics

Huilin Wang
Qitao Yu
Lina Shi
Qinhan Hou
Liang Dan
Chuqiao Liang
Xiaoyu Hong
Yun Zhao
Ruiling Ning

Frontiers in Oncology

doi 10.3389/fonc.2022.1054593

3,071 views
2 citations

Case Report

Published on 24 Nov 2022

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report

in Cancer Molecular Targets and Therapeutics

Ji Eun Shin
Ho Jung An
Hyung Soon Park
Hyunho Kim
Byoung Yong Shim

Frontiers in Oncology

doi 10.3389/fonc.2022.976450

3,568 views
8 citations

Correction

Published on 23 Nov 2022

Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

in Cancer Molecular Targets and Therapeutics

Giulia Pinton
Zhuo Wang
Cecilia Balzano
Sara Missaglia
Daniela Tavian
Renzo Boldorini
Dean A. Fennell
Martin Griffin
Laura Moro

Frontiers in Oncology

doi 10.3389/fonc.2022.1081632

1,679 views

Original Research

Published on 23 Nov 2022

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial

in Cancer Molecular Targets and Therapeutics

Jijin Wang
Di Huang
Wenjing Yang
Qingxu Song
Yibin Jia
Pengxiang Chen
Yufeng Cheng

Frontiers in Oncology

doi 10.3389/fonc.2022.1030798

1,711 views
1 citation

Original Research

Published on 23 Nov 2022

ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation

in Cancer Molecular Targets and Therapeutics

Daqi Jia
Leilei Li
Peng Wang
Qiang Feng
Xinyan Pan
Peng Lin
Shuling Song
Lilin Yang
Julun Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.1043177

2,826 views
6 citations

Systematic Review

Published on 21 Nov 2022

Prognostic significance of CDC20 expression in malignancy patients: A meta-analysis

in Cancer Molecular Targets and Therapeutics

Feng Xian
Xuegang Yang
Guohui Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.1017864

3,168 views
9 citations

Original Research

Published on 18 Nov 2022

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study

in Cancer Molecular Targets and Therapeutics

Xiongfei Yu
Yiran Chen
Jun Lu
Kuifeng He
Yanyan Chen
Yongfeng Ding
Ketao Jin
Haiyong Wang
Haibin Zhang
Haohao Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.985154

4,000 views
6 citations

Original Research

Published on 18 Nov 2022

Comparison of general anesthesia and continuous intravenous sedation for electrochemotherapy of head and neck skin lesions

in Cancer Molecular Targets and Therapeutics

Janez Benedik
Barbara Ogorevc
Simona Kranjc Brezar
Maja Cemazar
Gregor Sersa
Ales Groselj

Frontiers in Oncology

doi 10.3389/fonc.2022.1011721

2,474 views
7 citations

Original Research

Published on 17 Nov 2022

β-(4-fluorobenzyl) Arteannuin B induced interaction of ATF-4 and C/EBPβ mediates the transition of breast cancer cells from autophagy to senescence

in Cancer Molecular Targets and Therapeutics

Khalid Bashir Mir
Mir Mohd Faheem
Syed Mudabir Ahmad
Javeed Ur Rasool
Tanzeeba Amin
Souneek Chakraborty
Madhulika Bhagat
Zabeer Ahmed
Asif Ali
Anindya Goswami

Frontiers in Oncology

doi 10.3389/fonc.2022.1013500

3,732 views
6 citations

Review

Published on 17 Nov 2022

Utilization of macrocyclic peptides to target protein-protein interactions in cancer

in Cancer Molecular Targets and Therapeutics

Jiawen Yang
Qiaoliang Zhu
Yifan Wu
Xiaojuan Qu
Haixia Liu
Biao Jiang
Di Ge
Xiaoling Song

Frontiers in Oncology

doi 10.3389/fonc.2022.992171

8,879 views
13 citations

Review

Published on 16 Nov 2022

Impact of SOX2 function and regulation on therapy resistance in bladder cancer

in Cancer Molecular Targets and Therapeutics

Guodong Chen
Yan Chen
Ruiquan Xu
Guoxi Zhang
Xiaofeng Zou
Gengqing Wu

Frontiers in Oncology

doi 10.3389/fonc.2022.1020675

3,082 views
9 citations

Original Research

Published on 16 Nov 2022

Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines

in Cancer Molecular Targets and Therapeutics

Anna-Maria Barciszewska
Agnieszka Belter
Iwona Gawrońska
Małgorzata Giel-Pietraszuk
Mirosława Z. Naskręt-Barciszewska

Frontiers in Oncology

doi 10.3389/fonc.2022.1033035

3,246 views
13 citations

Original Research

Published on 15 Nov 2022

Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis

in Cancer Molecular Targets and Therapeutics

Dandan Jiang
Peizhi Ma

Frontiers in Oncology

doi 10.3389/fonc.2022.1057455

3,227 views
16 citations

Review

Published on 15 Nov 2022

Ferroptosis in osteosarcoma: A promising future

in Cancer Molecular Targets and Therapeutics

Xiang Liu
Shaowen Du
Shengdong Wang
Kaishan Ye

Frontiers in Oncology

doi 10.3389/fonc.2022.1031779

4,969 views
28 citations